Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 301 Binney Street CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://www.cyclerion.com |
IR: | See website |
Key People | ||
Regina Graul President | Anjeza Gjino Chief Financial Officer, Corporate Secretary | Cheryl Gault Chief Operating Officer |
Business Overview |
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company's portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cyclerion Therapeutics Inc revenues decreased from $297K to $0K. Net loss before extraordinary items decreased 31% to $12.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 81% to $646K (expense). |
Employees: | 1 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1.10M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$9.65M as of Dec 31, 2023 |
Net annual income (TTM): | -$12.59M as of Dec 31, 2023 |
Free cash flow (TTM): | -$21.25M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 2,710,096 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |